SECUKINUMAB PROVIDES HIGHER SYMPTOMATIC IMPROVEMENT VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 48 WEEKS ASSESSED BY TWO MATCHING-ADJUSTED INDIRECT COMPARISONS

被引：0

作者：

Thom, H. ^{[1
]}

Hunger, M. ^{[2
]}

Rosal, G. F. ^{[3
]}

Gandhi, K. ^{[4
]}

Jugl, S. M. ^{[5
]}

Nash, P. ^{[6
]}

机构：

[1] Univ Bristol, Bristol, Avon, England

[2] Mapi Grp, Munich, Germany

[3] Novartis Biociencias SA, Sao Paulo, Brazil

[4] Novartis Pharmaceut, E Hanover, NJ USA

[5] Novartis Pharma AG, Basel, Switzerland

[6] Univ Queensland, Brisbane, Qld, Australia

来源：

关键词：

D O I：

10.1016/j.jval.2017.08.2958

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMS3

引用

页码：A935 / A935

页数：1